Zanubrutinib plus venetoclax showed promising efficacy and manageable safety in treatment-naïve CLL/SLL, including patients with del(17p) and TP53 mutations.
The post CLL Combo Therapy Maintains Safety, Efficacy Regardless of TP53 Status first appeared on Physician’s Weekly.
